ReviewCurrent opinion in lipidology2012
Rationale for cholesteryl ester transfer protein inhibition.
Review in Current opinion in lipidology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13) C8 ]-evacetrapib as a tracer.Journal of labelled compounds & radiopharmaceuticals · 2016Trial
- Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib.European journal of clinical pharmacology · 2016Trial
- Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.The Journal of clinical investigation · 2015 · on this mapTrial
- Effects of a purified krill oil phospholipid rich in long-chain omega-3 fatty acids on cardiovascular disease risk factors in non-human primates with naturally occurring diabetes type-2 and dyslipidemia.Lipids in health and disease · 2017Article
- The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications.Coronary artery disease · 2016Review
- Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.Pharmacotherapy · 2016Article
- Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk.Human genetics · 2016Article
- LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?Current cardiology reports · 2015Review
- Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
- MicroRNA control of high-density lipoprotein metabolism and function.Circulation research · 2014Review
- Observational
- CETP inhibitors and cardiovascular disease: Time to think again.F1000Research · 2014Article
- Multi-locus candidate gene analyses of lipid levels in a pediatric Turkish cohort: lessons learned on LPL, CETP, LIPC, ABCA1, and SHBG.Omics : a journal of integrative biology · 2013Article
- Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.Seminars in liver disease · 2013Review
- A coding variant in SR-BI (I179N) significantly increases atherosclerosis in mice.Mammalian genome : official journal of the International Mammalian Genome Society · 2013Article
- Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.Clinical pharmacokinetics · 2013Article
- Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretion.Circulation research · 2013Article
- Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults.Lipids in health and disease · 2013Article
- HDL--is it too big to fail?Nature reviews. Endocrinology · 2013Review
- Functional genomics of the human high-density lipoprotein receptor scavenger receptor BI: an old dog with new tricks.Current opinion in endocrinology, diabetes, and obesity · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewRaising HDL cholesterol (HDL-C) has become an attractive therapeutic target to lower cardiovascular risk in addition to statins. Inhibition of the cholesteryl ester transfer protein (CETP), which mediates the transfer of cholesteryl esters from HDL to apolipoprotein B-containing particles, leads to a substantial increase in HDL-C levels. Various CETP inhibitors are currently being evaluated in phase II and phase III clinical trials. However, the beneficial effect of CETP inhibition on cardiovascular outcome remains to be established. RECENT
findingsTorcetrapib, the first CETP inhibitor tested in a phase III clinical trial (ILLUMINATE), failed in 2006 because of an increase in all-cause mortality and cardiovascular events that subsequently were attributed to nonclass-related off-target effects (particularly increased blood pressure and low serum potassium) related to the stimulation of aldosterone production. Anacetrapib, another potent CETP inhibitor, raises HDL-C levels by approximately 138% and decreases LDL cholesterol (LDL-C) levels by approximately 40%, without the adverse off-targets effects of torcetrapib (DEFINE study). The CETP modulator dalcetrapib raises HDL-C levels by approximately 30% (with only minimal effect on LDL-C levels) and proved safety in the dal-VESSEL and dal-PLAQUE trials involving a total of nearly 600 patients. Evacetrapib, a relatively new CETP inhibitor, exhibited favorable changes in the lipid profile in a phase II study. SUMMARY: The two ongoing outcome trials, dal-OUTCOMES (dalcetrapib) and REVEAL (anacetrapib), will provide more conclusive answers for the concept of reducing cardiovascular risk by raising HDL-C with CETP inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.